231 related articles for article (PubMed ID: 22093536)
1. Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease.
Kalinderi K; Fidani L; Katsarou Z; Bostantjopoulou S
Int J Clin Pract; 2011 Dec; 65(12):1289-94. PubMed ID: 22093536
[TBL] [Abstract][Full Text] [Related]
2. Genetics and Treatment Response in Parkinson's Disease: An Update on Pharmacogenetic Studies.
Politi C; Ciccacci C; Novelli G; Borgiani P
Neuromolecular Med; 2018 Mar; 20(1):1-17. PubMed ID: 29305687
[TBL] [Abstract][Full Text] [Related]
3. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease.
Białecka M; Droździk M; Kłodowska-Duda G; Honczarenko K; Gawrońska-Szklarz B; Opala G; Stankiewicz J
Acta Neurol Scand; 2004 Oct; 110(4):260-6. PubMed ID: 15355491
[TBL] [Abstract][Full Text] [Related]
4. How should we treat a patient with early Parkinson's disease?
Tsouli S; Konitsiotis S
Int J Clin Pract; 2010 Aug; 64(9):1210-9. PubMed ID: 20653797
[TBL] [Abstract][Full Text] [Related]
5. L-dopa therapy for Parkinson's disease: past, present, and future.
Nagatsua T; Sawadab M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S3-8. PubMed ID: 19131039
[TBL] [Abstract][Full Text] [Related]
6. Parkinson's disease: diagnosis and treatment.
Rao SS; Hofmann LA; Shakil A
Am Fam Physician; 2006 Dec; 74(12):2046-54. PubMed ID: 17186710
[TBL] [Abstract][Full Text] [Related]
7. Parkinson's disease. Therapeutic strategies to improve patient function and quality of life.
Danisi F
Geriatrics; 2002 Mar; 57(3):46-50; quiz 52. PubMed ID: 11899548
[TBL] [Abstract][Full Text] [Related]
8. Advances in the pharmacologic management of early Parkinson disease.
Hauser RA; Zesiewicz TA
Neurologist; 2007 May; 13(3):126-32. PubMed ID: 17495756
[TBL] [Abstract][Full Text] [Related]
9. [The new Parkinson's disease drugs].
Hasegawa K
Nihon Rinsho; 2000 Oct; 58(10):2066-71. PubMed ID: 11068448
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.
Contin M; Martinelli P; Mochi M; Riva R; Albani F; Baruzzi A
Mov Disord; 2005 Jun; 20(6):734-9. PubMed ID: 15747357
[TBL] [Abstract][Full Text] [Related]
11. Drug selection and timing of initiation of treatment in early Parkinson's disease.
Schapira AH; Olanow CW
Ann Neurol; 2008 Dec; 64 Suppl 2():S47-55. PubMed ID: 19127579
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors.
Talati R; Reinhart K; Baker W; White CM; Coleman CI
Parkinsonism Relat Disord; 2009 Aug; 15(7):500-5. PubMed ID: 19167259
[TBL] [Abstract][Full Text] [Related]
13. The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications.
Bialecka M; Kurzawski M; Klodowska-Duda G; Opala G; Tan EK; Drozdzik M
Pharmacogenet Genomics; 2008 Sep; 18(9):815-21. PubMed ID: 18698234
[TBL] [Abstract][Full Text] [Related]
14. Advances in the delivery of treatments for Parkinson's disease.
Johnston TH; Fox SH; Brotchie JM
Expert Opin Drug Deliv; 2005 Nov; 2(6):1059-73. PubMed ID: 16296809
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
Stocchi F; Marconi S
Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
[TBL] [Abstract][Full Text] [Related]
16. Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy.
Fischer PA
J Neural Transm Suppl; 1995; 46():381-9. PubMed ID: 8821073
[TBL] [Abstract][Full Text] [Related]
17. Introductory remarks: Catechol-O-methyltransferase inhibition--an innovative approach to enhance L-dopa therapy in Parkinson's disease with dual enzyme inhibition.
Nissinen E
Int Rev Neurobiol; 2010; 95():1-5. PubMed ID: 21095456
[TBL] [Abstract][Full Text] [Related]
18. Treatment of levodopa-induced motor complications.
Stocchi F; Tagliati M; Olanow CW
Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681
[TBL] [Abstract][Full Text] [Related]
19. Role of dopamine receptor agonists in the treatment of early Parkinson's disease.
Bonuccelli U; Del Dotto P; Rascol O
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S44-53. PubMed ID: 20123557
[TBL] [Abstract][Full Text] [Related]
20. Levodopa in the early treatment of Parkinson's disease.
Murata M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]